Overview

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

Status:
Recruiting
Trial end date:
2023-09-22
Target enrollment:
Participant gender:
Summary
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide, Formoterol Fumarate Drug Combination